India Approves Dengue Vaccine Protecting 100M People Yearly

India just took a major leap forward in fighting dengue, a disease that sends thousands to hospitals every monsoon season and now affects three times more people than it did 20 years ago.

On July 20th, India approved QDENGA, the country's first dengue prevention vaccine that protects against all four strains of the virus. Unlike older vaccines, this one requires no blood test before administration and works whether you've had dengue before or not.

The approval marks a breakthrough partnership between Japanese pharmaceutical company Takeda and Hyderabad-based Biological E. Together, they're building capacity to produce 50 million doses yearly in India as part of the Make in India initiative, contributing to a global target of 100 million doses by 2030.

The vaccine arrives at a critical moment. India now reports one-third of all dengue cases worldwide, with numbers surging 11-fold over two decades due to urbanization, climate change, and expanding mosquito habitats. Seasonal outbreaks strain hospitals across the country, particularly during and after monsoons.

QDENGA demonstrated impressive results in trials involving over 28,000 people across dengue-endemic countries. The vaccine showed 84.1% protection against hospitalization and 61% overall protection against confirmed dengue infections. Protection remained strong over seven years of monitoring across all four virus serotypes.

More than 40 countries including the European Union, UK, Brazil, and Indonesia have already approved the vaccine. Since its 2022 launch, over 32 million doses have been distributed globally. The World Health Organization has prequalified it, meaning global health organizations like UNICEF can now purchase it for immunization programs.

Anyone aged 4 to 60 can receive the vaccine through two doses given three months apart. India's Phase III trial specifically tested safety and immune response in Indian populations, confirming the vaccine's effectiveness in local conditions.

The Ripple Effect

This approval represents more than one vaccine. It showcases India's growing strength as a global vaccine powerhouse, building on capabilities proven during COVID-19. The country is now producing vaccines at scale while advancing research that benefits both its own population and the world.

The dengue vaccine adds a powerful new tool to India's public health arsenal, working alongside mosquito control, early diagnosis, and community awareness programs. Together, these efforts create a comprehensive defense against a disease that has challenged the region for generations.

India's vaccine sector continues proving that innovation and manufacturing excellence can emerge from anywhere, delivering hope to millions who need it most.